Bizarre Patents
Neuroimaging as a Marketing Tool
Neuroimaging as a means for validating whether a stimulus such as advertisement, communication, or product evokes a certain mental response such as emotion, preference, or memory, or to predict the consequences of the stimulus on later behavior such as consumption or purchasing.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120021005 | MYCOPLASMA GALLISEPTICUM FORMULATION The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically accept... | 01/26/2012 |
| 20110300179 | Novel Compositions and Uses Thereof The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid m... | 12/08/2011 |
| 20110223195 | COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian... | 09/15/2011 |
| 20110150933 | CATTLE VACCINES This document provides live non-pathogenic M. bovis bacteria and compositions containing live non-pathogenic M. bovis bacteria. This document also provides methods of using live non-pathogenic M. bovis bacteria to immunize cattle against infectious ... | 06/23/2011 |
| 20110129494 | Vaccine Formulations Comprising Saponin-containing Adjuvants The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present inventi... | 06/02/2011 |
| 20110104207 | GYRASE INHIBITORS AND USES THEREOF The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention al... | 05/05/2011 |
| 20110059128 | VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE (CIRD) A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycopla... | 03/10/2011 |
| 20100272759 | MODIFIED LIVE VACCINE OF MYCOPLASMA BOVIS, METHODS OF PRODUCING MODIFIED LIVE MYCOPLASMA BOVIS VACCINES, COMBINATION VACCINES AND METHODS OF TREATMENT The present invention relates to new attenuated M. bovis bacteria strains passaged at least 110 times. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of any of those attenuated M. bovis bacteria strain, thei... | 10/28/2010 |
| 20100266629 | Cattle Reproductive Disease Vaccines The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Viru... | 10/21/2010 |
| 20100062019 | NEW VACCINE FORMULATIONS The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicl... | 03/11/2010 |
| 20100062018 | MYCOPLASMA HYOPNEUMONIAE BACTERIN VACCINE The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an... | 03/11/2010 |
| 20090304737 | Vaccine Against Mycoplasma PRRSV The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.... | 12/10/2009 |
| 20090220550 | Vaccines for Mycoplasma bovis and methods of use The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joi... | 09/03/2009 |
| 20090130148 | MYCOPLASMA BOVIS VACCINE AND METHODS OF USE THEREOF The present invention relates to new attenuated M. bovis bacteria strains. Moreover, the present invention also provides immunogenic compositions comprising live bacteria of an of those attenuated M. bovis bacteria strain, their manufacture and use for the... | 05/21/2009 |
| 20090117152 | Mycoplasma Hyopneumoniae Avirulent Adjuvanted Live Vaccine Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an anima... | 05/07/2009 |
| 20090068232 | ATTENUATED MYCOPLASMA GALLISEPTICUM STRAINS The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more prote... | 03/12/2009 |
| 20090068231 | LIVE ATTENUATED MYCOPLASMA STRAINS The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal ... | 03/12/2009 |
| 20080311156 | VACCINES The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by ... | 12/18/2008 |
| 20080226671 | Vaccines for Mycoplasma bovis and methods of use The invention of novel, effective vaccines against Mycoplasma. bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, jo... | 09/18/2008 |
| 20080193463 | Mycoplasma Subunit Vaccine The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-α-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-α-glycerophosphate oxidase for the manufacturing of such vaccines, to methods fo... | 08/14/2008 |
| 20080187555 | New Vaccine Formulations The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicl... | 08/07/2008 |
| 20080181916 | Canine Lyme Disease Vaccine The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.... | 07/31/2008 |
| 20080044440 | Vaccine Formulated For Administration To Mucosa Of The Lungs There is disclosed vaccines formulated for administration to the mucosa of the lungs of a mammal, and the use thereof in methods for prophylaxis or treatment of an infection by at least one pathogenic microorganism. The vaccines comprise a cellular fraction of the micro... | 02/21/2008 |
